News Grower

Independent coverage of AI, startups, and technology.

Ars Technica Apr 15, 2026 at 14:11 Big Tech Stable Warm

What’s the deal with Alzheimer’s disease and amyloid?

For decades, scientists have concentrated on what now looks to be a blind alley.

Signal weather

Stable

The story has moved beyond the first headline and now acts as a reliable context anchor.

By Jonathan M. Gitlin Original source
What’s the deal with Alzheimer’s disease and amyloid?

At the end of last month, a scientific journal pulled a research paper on Alzheimer's disease. The retraction came from Neurobiology of Aging, which removed a 2011 paper claiming to show that a version of a protein called amyloid-β was responsible for memory loss in Alzheimer's disease. On its own, that might not seem notable; bad papers can make it through peer review and are only caught after publication. But this wasn't an isolated case. Over the past few years, multiple studies arguing that amyloid-β is the central driver of Alzheimer's disease have been retracted. Some scientists have even been indicted for fraud over the issue. All the while, none of the drugs targeting this protein and its pathway have had any real clinical effect. Read full article Comments

Stay on the signal

Follow What’s the deal with Alzheimer’s disease and amyloid?

Follow this story beyond a single article: new follow-ups, adjacent sources, and the evolving storyline.

We send a confirmation link first, then only meaningful digests.

Story map

Understand this topic fast

A quick entry into the story: why it matters now, who is involved, and where to go next for context.

Why it matters now

This story is still moving and pulling follow-up coverage.
There are already 6 connected articles in the same storyline to continue from here.
The story keeps orbiting around Alzheimer, Amyloid, and Ars Technica, so the entity pages are the fastest way to build context.
Ars Technica already has 4 follow-up stories on the same theme.

Topic constellation

Open the live map for this story

See which entities, story threads, sources, and follow-up articles shape this story right now.

Click nodes to continue

Entity Cluster Article Hub Source

Story timeline

Continue with this story

A short sequence of events and follow-up stories to understand the arc quickly.

May 31, 2026 at 16:19 Hacker News

Creatine raise brain energy levels and slow Alzheimer's cognitive decline by 30%

Comments

May 31, 2026 at 11:15 Ars Technica

On its 40th anniversary, we reassess 1986's SpaceCamp

Is it a hidden gem, a cult classic, or hopelessly dumb? We vote "all of the above."

May 31, 2026 at 10:00 Ars Technica

They call it stupid hot for a reason: Heat muddles animal brains

As temperatures rise, some creatures pick fights while others struggle to learn.

May 30, 2026 at 11:00 Ars Technica

Grifters, cynics, and true believers: The family tree of vaccine opponents

A new book looks into the long history of people who have opposed vaccines.

May 30, 2026 at 10:00 Ars Technica

Environmentalists turn out in force to oppose Trump coal ash rollbacks

Trump admin wants to rely on states for coal ash monitoring, enforcement, allow them to bypass national standards.

Apr 15, 2026 at 14:11 Ars Technica

What’s the deal with Alzheimer’s disease and amyloid?

For decades, scientists have concentrated on what now looks to be a blind alley.

How reliable this looks

Signal and trust for Ars Technica

This source works at a rapid pace: 100% of recent stories land in the hot window, and 0% carry visible search signal.

Trusted

Reliability

92

Freshness

100

Sources in storyline

2

Related articles

More stories that share tags, source, or category context.

More from Ars Technica

Fresh reporting and follow-up coverage from the same newsroom.

Open source page